100% Partial Response or Better Announced in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Ph 1b Clinical Trial
“These interim results are encouraging,” stated Dr. Jamie Oliver, Starton’s Chief Medical Officer. “To date, lenalidomide is a cornerstone in treating MM. As a standard of care, Revlimid® is widely used due to its effectiveness in combination with other therapies. However, its toxicity profile is unbearable for some, leaving a notable percentage of patients’ intolerant to lenalidomide. STAR-LLD is demonstrating lower toxicity at therapeutic doses, which could potentially improve lenalidomide’s use in MM.”
Share:
More News
CEO Snehal Patel commented, “We are very encouraged to see that the preliminary results from FLAMINGO-01 show immune responses in both HLA-A*02 and non-HLA-A*02 patients. We are now considering the merits of adding a randomized placebo arm for non-HLA-A*02 patients, transforming this current open label third arm into effectively a
“At Ferring, we are committed to meeting the unmet needs in bladder cancer care and equipping uro-oncologists with critical evidence they need to deliver effective, and life-changing treatment,” said Joern Jakobsen, M.D., Ph.D., Vice President and Head of Global Research and Medical for Uro-Oncology and Urology, Ferring Pharmaceuticals. “These new
“We recognise the significance of Mosaic’s platform, which has identified these two assets as anchor components of a pipeline of potential combination products,” said Dr. Harren Jhoti, co-founder, president and chief executive officer of Astex. “Both drug targets are well-characterised drivers of many cancers, and we are excited to be
“We do not view today’s unsatisfactory outcome as a failure of Globo H,” Dr. Heidi Wang, CEO of OBI Pharma added. “There may come a time, with a deeper scientific understanding of the Globo H function, it may play a meaningful role once again.”
